ストックスクリーナーアプリを入手
53.38
2.99%
1.55
前日終値:
$51.83
開ける：
$51.83
24時間の取引高:
2.87M
Relative Volume:
1.00
時価総額：
$10.20B
収益：
$217.77M
当期純損益:
$-438.86M
株価収益率:
-22.15
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
+3.13%
1か月 パフォーマンス:
+8.47%
6か月 パフォーマンス:
+52.65%
1年 パフォーマンス:
+70.54%
1日の値動き範囲:
$51.50
$53.97
1週間の範囲:
$49.75
$53.97
52週間の値動き範囲:
$21.72
$53.97
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
53.38 | 9.91B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
BridgeBio’s encaleret shows promise in hypoparathyroidism treatment By Investing.com - Investing.com Nigeria
BridgeBio’s encaleret shows promise in hypoparathyroidism treatment - Investing.com India
BridgeBio Pharma Inc. recovery potential after sell offJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
BridgeBio Pharma Reports Promising Phase 2 Results for Encaleret in Post-Surgical Hypoparathyroidism, Plans Registrational Study for 2026 - Quiver Quantitative
BridgeBio Pharma says intends to initiate registrational clinical study of Encaleret in 2026 - MarketScreener
80% Success Rate: BridgeBio's Encaleret Normalizes Calcium Levels in Breakthrough Hypoparathyroidism Study - Stock Titan
Chart based analysis of BridgeBio Pharma Inc. trendsTrade Volume Summary & High Accuracy Trade Signal Alerts - Newser
Why is BridgeBio Pharma Inc. stock going down2025 Institutional Moves & Technical Pattern Recognition Alerts - خودرو بانک
Is BridgeBio Pharma Inc. stock a top performer YTDAnalyst Downgrade & Real-Time Market Trend Scan - خودرو بانک
BridgeBio Pharma stock hits 52-week high at $52.85 By Investing.com - Investing.com Nigeria
BridgeBio Pharma Inc. stock momentum explainedJuly 2025 Action & Smart Allocation Stock Tips - Newser
News impact scoring models applied to BridgeBio Pharma Inc.Market Growth Summary & Expert Curated Trade Ideas - Newser
Is it time to cut losses on BridgeBio Pharma Inc.Weekly Gains Report & High Accuracy Trade Signal Alerts - Newser
BridgeBio Pharma stock hits 52-week high at $52.85 - Investing.com
What candlestick patterns are forming on BridgeBio Pharma Inc.Inflation Watch & Risk Adjusted Swing Trade Ideas - Newser
When is the best time to exit BridgeBio Pharma Inc.Global Markets & Long-Term Safe Investment Plans - Newser
Published on: 2025-09-05 07:26:11 - خودرو بانک
Using RSI to spot recovery in BridgeBio Pharma Inc.July 2025 Short Interest & AI Enhanced Execution Alerts - Newser
Backtesting results for BridgeBio Pharma Inc. trading strategies2025 Fundamental Recap & Accurate Trade Setup Notifications - Newser
Published on: 2025-09-04 06:09:36 - Newser
Analyzing recovery setups for BridgeBio Pharma Inc. investorsBull Run & Risk Controlled Swing Trade Alerts - Newser
What’s the analyst consensus on BridgeBio Pharma Inc.2025 Growth vs Value & Weekly Market Pulse Alerts - خودرو بانک
Live market analysis of BridgeBio Pharma Inc.2025 Top Gainers & Fast Gaining Stock Reports - Newser
BridgeBio Pharma shares fall 1.95% after-hours following an investor webinar announcement. - AInvest
BridgeBio Pharma (BBIO) Receives a Rating Update from a Top Analyst - The Globe and Mail
Applying Elliott Wave Theory to BridgeBio Pharma Inc.July 2025 Action & Pattern Based Trade Signal System - Newser
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - The Manila Times
BridgeBio Pharma (BBIO) Rating Reiterated as 'Buy' by HC Wainwright & Co. | BBIO Stock News - GuruFocus
Phase 3 Trial Update: BridgeBio's Breakthrough ADH1 Drug Encaleret Featured in NIH Expert Webinar - Stock Titan
Is BridgeBio Pharma Inc. a good ESG investmentProfit Target & Free Weekly Watchlist of Top Performers - خودرو بانک
Market reaction to BridgeBio Pharma Inc.’s recent newsPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Strategies to average down on BridgeBio Pharma Inc.2025 Top Decliners & Proven Capital Preservation Methods - Newser
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) - GuruFocus
Can BridgeBio Pharma Inc. withstand a market correctionMarket Sentiment Report & Entry and Exit Point Strategies - خودرو بانک
Short Interest Drops in BridgeBio Pharma Inc. After RallyMarket Performance Report & Weekly High Momentum Picks - beatles.ru
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism - The Manila Times
BridgeBio Pharma Presents Phase 2 Data on Post-Surgical Hypoparathyroidism and Skeletal Dysplasia at ASBMR Annual Meeting 2025 - Quiver Quantitative
New Treatment Hope: BridgeBio's Encaleret Shows Promise in Post-Surgical Hypoparathyroidism Phase 2 Trial - Stock Titan
What’s next for BridgeBio Pharma Inc. stock priceLayoff News & Community Verified Watchlist Alerts - Newser
Published on: 2025-09-02 04:42:43 - Newser
Tick level data insight on BridgeBio Pharma Inc. volatilityEarnings Overview Summary & Weekly High Return Opportunities - Newser
Is BridgeBio Pharma Inc. a defensive stock2025 Breakouts & Breakdowns & Verified Short-Term Plans - خودرو بانک
BridgeBio Pharma: Promising Phase 3 Data and Strong Financial Performance Justify Buy Rating - TipRanks
Tools to monitor BridgeBio Pharma Inc. recovery probabilityPortfolio Risk Report & Daily Chart Pattern Signal Reports - Newser
How does BridgeBio Pharma Inc. score in quality rankingsJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - khodrobank.com
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
大文字化:
|
ボリューム (24 時間):